# EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

> **NCT02521090** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Adult Brain Glioblastoma
- Adult Gliosarcoma
- Recurrent Brain Neoplasm

## Interventions

- **BIOLOGICAL:** EGFRBi-Armed Autologous T Cells
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02521090
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-08
- **Primary completion:** 2016-03
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to lack of funding and a primary co-investigator of the trial leaving the institution.
- **Last updated:** 2016-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521090, "EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02521090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*